Correlation Between Mineralys Therapeutics and Edgewise Therapeutics

Can any of the company-specific risk be diversified away by investing in both Mineralys Therapeutics and Edgewise Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Mineralys Therapeutics and Edgewise Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Mineralys Therapeutics Common and Edgewise Therapeutics, you can compare the effects of market volatilities on Mineralys Therapeutics and Edgewise Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Mineralys Therapeutics with a short position of Edgewise Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Mineralys Therapeutics and Edgewise Therapeutics.

Diversification Opportunities for Mineralys Therapeutics and Edgewise Therapeutics

0.25

Correlation Coefficient

Mineralys Therapeutics  Edgewise Therapeutics

Modest diversification

The 3 months correlation between Mineralys and Edgewise is 0.25. Overlapping area represents the amount of risk that can be diversified away by holding Mineralys Therapeutics Common and Edgewise Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Edgewise Therapeutics and Mineralys Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Mineralys Therapeutics Common are associated (or correlated) with Edgewise Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Edgewise Therapeutics has no effect on the direction of Mineralys Therapeutics i.e., Mineralys Therapeutics and Edgewise Therapeutics go up and down completely randomly.

Pair Corralation between Mineralys Therapeutics and Edgewise Therapeutics

Given the investment horizon of 90 days Mineralys Therapeutics is expected to generate 1.54 times less return on investment than Edgewise Therapeutics. But when comparing it to its historical volatility, Mineralys Therapeutics Common is 1.5 times less risky than Edgewise Therapeutics. It trades about 0.17 of its potential returns per unit of risk. Edgewise Therapeutics is currently generating about 0.17 of returns per unit of risk over similar time horizon. If you would invest  647.00  in Edgewise Therapeutics on February 21, 2024 and sell it today you would earn a total of  1,191  from holding Edgewise Therapeutics or generate 184.08% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Mineralys Therapeutics Common  vs.  Edgewise Therapeutics

Mineralys Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Mineralys Therapeutics Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in June 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Edgewise Therapeutics

Risk-Adjusted Performance

3 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Edgewise Therapeutics are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unsteady basic indicators, Edgewise Therapeutics may actually be approaching a critical reversion point that can send shares even higher in June 2024.

Pair Trading with Mineralys Therapeutics and Edgewise Therapeutics

The main advantage of trading using opposite Mineralys Therapeutics and Edgewise Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Mineralys Therapeutics position performs unexpectedly, Edgewise Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Edgewise Therapeutics will offset losses from the drop in Edgewise Therapeutics' long position.

The idea behind Mineralys Therapeutics Common and Edgewise Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.